ES2190479T3 - Moduladores de rxr selectivos a dimeros y metodos para su uso. - Google Patents

Moduladores de rxr selectivos a dimeros y metodos para su uso.

Info

Publication number
ES2190479T3
ES2190479T3 ES96935837T ES96935837T ES2190479T3 ES 2190479 T3 ES2190479 T3 ES 2190479T3 ES 96935837 T ES96935837 T ES 96935837T ES 96935837 T ES96935837 T ES 96935837T ES 2190479 T3 ES2190479 T3 ES 2190479T3
Authority
ES
Spain
Prior art keywords
rxr
dimers
methods
rxr modulators
modulators selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96935837T
Other languages
English (en)
Inventor
Stacie Canan-Koch
Chan Kou Hwang
Marcus F Boehm
Beth Ann Badea
Laura J Dardashti
Lin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27485410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2190479(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2190479T3 publication Critical patent/ES2190479T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/33—Polycyclic acids
    • C07C63/49—Polycyclic acids containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/66—Polycyclic acids with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/34—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic
    • C07C65/36—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS MODULADORES RXR SELECTIVOS PARA DIMEROS, QUE PRESENTAN ACTIVIDAD AGONISTA PARCIAL Y/O ANTAGONISTA EN EL CONTEXTO DE UN HOMODIMERO RXR Y/O HETERODIMEROS RXR. ASIMISMO, SE PROPORCIONAN COMPOSICIONES FARMACEUTICAS QUE INCORPORAN DICHOS COMPUESTOS MODULADORES SELECTIVOS PARA DIMEROS RXR Y METODOS DE UTILIZACION TERAPEUTICA DE LOS MISMOS.
ES96935837T 1995-10-06 1996-09-17 Moduladores de rxr selectivos a dimeros y metodos para su uso. Expired - Lifetime ES2190479T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US489795P 1995-10-06 1995-10-06
US988496P 1996-01-10 1996-01-10
US1831896P 1996-05-24 1996-05-24
US2183996P 1996-07-10 1996-07-10

Publications (1)

Publication Number Publication Date
ES2190479T3 true ES2190479T3 (es) 2003-08-01

Family

ID=27485410

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96935837T Expired - Lifetime ES2190479T3 (es) 1995-10-06 1996-09-17 Moduladores de rxr selectivos a dimeros y metodos para su uso.

Country Status (14)

Country Link
US (2) US6545049B1 (es)
EP (2) EP1336600A3 (es)
JP (1) JP2002515025A (es)
KR (1) KR100625255B1 (es)
AT (1) ATE236115T1 (es)
AU (1) AU726450B2 (es)
BR (1) BR9610875A (es)
CA (1) CA2233888A1 (es)
DE (1) DE69627193T2 (es)
DK (1) DK0873295T3 (es)
ES (1) ES2190479T3 (es)
NO (1) NO313186B1 (es)
PT (1) PT873295E (es)
WO (1) WO1997012853A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
AU7074496A (en) 1995-09-18 1997-04-09 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
ES2216062T3 (es) * 1995-09-18 2004-10-16 Ligand Pharmaceuticals, Inc. Tratamiento de la niddm con agonistas del rxr.
US6005007A (en) * 1997-07-18 1999-12-21 Farmer; Luc J. Retinoids, methods for their production and use
WO1999005161A1 (en) * 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
US5998654A (en) * 1997-07-25 1999-12-07 Ligand Pharmaceuticals Incorporated Retinoic acid receptor antagonist compounds and methods
ATE334673T1 (de) 1997-11-12 2006-08-15 Hoffmann La Roche Behandlung von t-helfer zel typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
EP1077919A1 (en) * 1998-05-11 2001-02-28 Novo Nordisk A/S New compounds, their preparation and use
JP2002514617A (ja) * 1998-05-11 2002-05-21 ノボ ノルディスク アクティーゼルスカブ 新規化合物、その製造及び使用
EP1093362A1 (en) 1998-06-12 2001-04-25 Ligand Pharmaceuticals Incorporated Treatment of anti-estrogen resistant breast cancer using rxr modulators
FR2780512B1 (fr) * 1998-06-25 2003-10-17 Lipha Utilisation de recepteurs de la famille rev-erb pour le criblage de substances utiles dans le traitement des dysfonctionnements du metabolisme lipidique
US6147224A (en) * 1998-10-01 2000-11-14 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6048873A (en) * 1998-10-01 2000-04-11 Allergan Sales, Inc. Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
US6403638B1 (en) 1998-10-01 2002-06-11 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
WO2000026173A1 (en) * 1998-11-03 2000-05-11 Ligand Pharmaceuticals Incorporated Novel retinoids, methods for their production and use
DE60035271D1 (en) 1999-04-28 2007-08-02 Inst Med Molecular Design Inc Pyrimidincarbonsäurederivate
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
MXPA02002032A (es) 1999-08-27 2003-05-19 Ligand Pharm Inc Compuestos moduladores del receptor de androgeno y metodos.
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
AU1291901A (en) * 1999-09-01 2001-03-26 University Of British Columbia, The Compositions and methods for modulating hdl cholesterol and triglyceride levels
EP1216221A2 (en) * 1999-09-14 2002-06-26 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
RU2168989C1 (ru) * 1999-12-22 2001-06-20 Государственный научный центр лекарственных средств Средство для лечения сердечно-сосудистых заболеваний
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
EP1385549A2 (en) * 2001-03-12 2004-02-04 Novartis AG Combination of nateglinide or repaglinide with at least one further antidiabetic compound
EP1368296A1 (en) * 2001-03-14 2003-12-10 Eli Lilly And Company Fluorinated trienes and their use as rxr modulators
AU2002319583B2 (en) * 2001-07-20 2005-08-25 Eli Lilly And Company (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid X receptor modulators
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
US6759547B1 (en) 2003-01-14 2004-07-06 Allergan, Inc. 5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
US7019034B2 (en) 2003-01-28 2006-03-28 Allergan, Inc. Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6759546B1 (en) 2003-02-04 2004-07-06 Allergan, Inc. 3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6884820B2 (en) 2003-04-03 2005-04-26 Allergan, Inc. 5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6734193B1 (en) 2003-06-03 2004-05-11 Allergan, Inc. (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6887896B1 (en) 2003-10-29 2005-05-03 Allergan, Inc. 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
EA011010B1 (ru) 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
EP1621191A1 (en) * 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
EP1891067B1 (en) 2005-06-17 2016-01-13 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US20070185055A1 (en) * 2006-02-06 2007-08-09 Guang Liang Jiang Method for treating cachexia with retinoid ligands
EP2262364B1 (en) * 2008-03-07 2016-03-02 vTv Therapeutics LLC Oxadiazoanthracene compounds for the treatment of diabetes
US20110064806A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
US9174917B2 (en) 2010-02-19 2015-11-03 Arizona Board Of Regents On Behalf Of Arizona State University Bexarotene analogs
US9573906B2 (en) 2011-09-15 2017-02-21 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Therapeutic compounds
JP5877466B2 (ja) * 2012-02-29 2016-03-08 国立大学法人 岡山大学 テルペノイド由来レチノイド化合物
RU2721283C2 (ru) * 2014-01-14 2020-05-18 Конекшис Лайф Сайенсиз Пвт. Лтд. Замещенные бициклические гетероарильные соединения в качестве агонистов rxr
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods
CA2962150C (en) 2014-10-10 2023-07-04 High Force Research Limited Fluorescent synthetic retinoids
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
WO2018155260A1 (ja) * 2017-02-23 2018-08-30 株式会社Ihi Ｏｈラジカル検出プローブ、ｏｈラジカル測定装置、および、ｏｈラジカル測定方法
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
IL277038B2 (en) * 2018-03-01 2023-12-01 DJ Therapeutics LLC Bexarotene derivatives and their use in treating cancer
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845089A (en) * 1972-07-27 1974-10-29 Zoecon Corp Phenylheptadienoates
US4105681A (en) * 1975-08-01 1978-08-08 Hoffmann-La Roche Inc. 9-phenyl 5,6-dimethyl-nona-2,4,6,8-tetraeonic acid compounds
US4215215A (en) * 1975-08-01 1980-07-29 Hoffmann-La Roche Inc. 9-Phenyl-nonate traene compounds
LU77254A1 (es) * 1977-05-04 1979-01-18
US4326055A (en) * 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
DE3202100A1 (de) * 1982-01-23 1983-08-04 Basf Ag, 6700 Ludwigshafen Substituierte benzoesaeure-4-hydroxyanilide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
CH651034A5 (de) 1982-05-12 1985-08-30 Hoffmann La Roche Chroman-, thiochroman- oder 1,2,3,4-tetrahydrochinolinderivate und ihre verwendung als arzneimittel-wirkstoffe.
US4534979A (en) 1982-06-28 1985-08-13 Usv Pharmaceutical Corp. Polyene compounds useful in the treatment of psoriasis and allergic responses
US4539134A (en) * 1982-12-02 1985-09-03 Halliburton Company Methods and cleaning compositions for removing organic materials from metallic surfaces
US4539154A (en) 1983-06-15 1985-09-03 Hoffmann-La Roche Inc. Polyene compounds
US4648996A (en) * 1984-07-27 1987-03-10 Hoffmann-La Roche Inc. Phenyl substituted-2,4,6,8-nonatetraenoic acid
CH667868A5 (fr) 1984-09-05 1988-11-15 Oreal Derives du benzonorbornene, leurs procedes de preparation et compositions medicamenteuse et cosmetique les contenant.
DE3434944A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen L-substituierte tetralinderivate, ihre herstellung und verwendung
FR2580277B1 (fr) 1985-04-15 1988-06-10 Oreal Nouveaux derives naphtaleniques a action retinoique, le ur procede de preparation et compositions medicamenteuse et cosmetique les contenant
LU86022A1 (fr) 1985-07-25 1987-02-04 Cird Derives aromatiques polycyliques,leur procede de preparation et leur application dans les domaines pharmaceutique et cosmetique
JPS62215581A (ja) 1986-03-18 1987-09-22 Koichi Shiyudo フラボンカルボン酸誘導体
FR2599031B1 (fr) * 1986-05-23 1988-07-22 Oreal Nouveaux composes naphtyl aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
FR2601670B1 (fr) 1986-07-17 1988-10-07 Cird Nouveaux derives bicycliques aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
FR2605626B1 (fr) 1986-10-27 1989-06-02 Oreal Nouveaux derives aromatiques bicycliques, leur procede de preparation et leur utilisation en cosmetique et en medecine humaine et veterinaire
FR2614618B1 (fr) 1987-04-30 1989-07-07 Cird Derives heterocycliques polycycliques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire
US4977276A (en) * 1987-05-11 1990-12-11 The Board Of Regents For The Oklahoma Agricultural And Mechanical Colleges Acting For And On Behalf Of Oklahoma State Univ. Heteroarotinoids as anticancer agents
LU87040A1 (fr) 1987-11-04 1989-06-14 Oreal Esters aromatiques polycycliques d'antibiotiques macrolidiques et lincosamidiques,leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
DE4036779A1 (de) 1990-11-17 1992-05-21 Basf Ag Verwendung von arylpolyencarbonsaeuren und ihren derivaten als lichtschutzmittel in kosmetischen zubereitungen
CA2114936C (en) 1991-08-23 2004-02-10 Ronald M. Evans Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones
US5668175A (en) 1991-08-23 1997-09-16 The Salk Institute For Biological Studies Use of selective ligands for treatment of disease states responsive to steroid or steroid-like retinoids
ATE195716T1 (de) * 1992-04-22 2000-09-15 Ligand Pharm Inc Retinoid-x rezeptor selektive verbindungen
CA2093577C (en) 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
US5552271A (en) 1992-06-16 1996-09-03 La Jolla Cancer Research Foundation RXR homodimer formation
NZ248794A (en) 1992-09-29 1995-01-27 Adir 3-carboxy-(and phosphonoxy-)alkatriene-substituted chromene derivatives and medicaments
CA2149882A1 (en) 1992-11-25 1994-06-09 Magnus Pfahl Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
US5466861A (en) * 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
WO1994015901A1 (en) * 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
CA2153235C (en) * 1993-01-11 2005-08-23 Marcus F. Boehm Compounds having selectivity for retinoid x receptors
CA2153236A1 (en) * 1993-01-11 1995-02-09 Marcus F. Boehm Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
WO1995015901A1 (en) * 1993-12-08 1995-06-15 Beloit Technologies, Inc. Method and apparatus for effecting a set change in a paper winder
FR2719042B1 (fr) * 1994-04-25 1996-05-15 Rhone Poulenc Chimie Procédé de préparation d'un acide alpha-(hydroxyphénoxy)- alcanecarboxylique optiquement actif.
FR2719041B1 (fr) * 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés polyéniques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
FR2723315B1 (fr) 1994-08-02 1996-10-25 Cird Galderma Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes
PL180048B1 (en) 1994-08-10 2000-12-29 Fhoffmann La Roche Ag Ligands of retinic acid x-receptors
US5977125A (en) 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
IL116259A (en) 1994-12-19 2000-07-16 American Cyanamid Co Analogs of 9-cis retinoic acid and their use
US5968908A (en) 1994-12-19 1999-10-19 American Cyanamid Company Restricted 9-cis retinoids
KR19980701549A (ko) 1995-01-20 1998-05-15 슈타르 피아 퇴행성 뇌질환의 치료 또는 예방용 약학적 조성물의 제조를 위한 3,4-디페닐크로만의 이용(use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of cerebral degenerative disorders)
FR2729664A1 (fr) * 1995-01-20 1996-07-26 Cird Galderma Composes bicycliques-aromatiques a forte activite biologique compositions pharmaceutiques et cosmetiques les contenant et utilisations
EP1077919A1 (en) 1998-05-11 2001-02-28 Novo Nordisk A/S New compounds, their preparation and use

Also Published As

Publication number Publication date
JP2002515025A (ja) 2002-05-21
AU7362496A (en) 1997-04-28
KR19990064010A (ko) 1999-07-26
EP0873295B1 (en) 2003-04-02
NO313186B1 (no) 2002-08-26
WO1997012853A1 (en) 1997-04-10
EP0873295A1 (en) 1998-10-28
DE69627193T2 (de) 2004-01-29
ATE236115T1 (de) 2003-04-15
DE69627193D1 (de) 2003-05-08
KR100625255B1 (ko) 2008-01-30
BR9610875A (pt) 1999-07-13
CA2233888A1 (en) 1997-04-10
EP1336600A3 (en) 2004-07-07
DK0873295T3 (da) 2003-07-14
NO981501D0 (no) 1998-04-02
US20040019072A1 (en) 2004-01-29
US6545049B1 (en) 2003-04-08
NO981501L (no) 1998-06-02
PT873295E (pt) 2003-08-29
AU726450B2 (en) 2000-11-09
EP1336600A2 (en) 2003-08-20

Similar Documents

Publication Publication Date Title
ES2190479T3 (es) Moduladores de rxr selectivos a dimeros y metodos para su uso.
HN1998000157A (es) Agonistas de prostaglandinas
ES2115298T3 (es) Nuevos derivados de 1-fenil-3-dimetil-amino-propano, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CU23393A3 (es) Compuestos inhibidores de la raf kinasa y composiciones farmacéuticas que los contienen
AR020020A1 (es) Composicion para el tratamiento de cancer y metodo usando moduladores de transduccion de senal y aceites esenciales de plantas naturales como sinergistas para tratamientos convencionales
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
PT918774E (pt) Compostos moduladores do receptor para androgenio e metodos
MX9709874A (es) N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
UY24986A1 (es) Compuestos
AR027162A1 (es) Compuestos de 2-fenil-3-fenoxilo-feniltio-benzotiofeno, sales farmaceuticamente aceptables de los mismos y composiciones farmaceuticas que los contienen
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
AR002277A1 (es) Compuestos utiles como inhibidores de la trombina, composiciones farmaceuticas que los contienen y sustancias peptidicas y peptidomimeticasinhibidoras de la serinproteasa.
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
ES2153076T3 (es) Agentes herbicidas basados en bencisoxazol y bencisotiazol sustituidos.
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
AR004498A1 (es) Compuestos de aminofosfonato y composiciones farmaceuticas que los contienen, el uso de los mismos, y un procedimiento para su preparacion
MX9201356A (es) Derivados de piperidina, procedimiento para su preparacion y composicion farmaceutica que los contiene.
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
ES2177656T3 (es) Derivados de antraciclinona y su utilizacion en el tratamiento de la amiloidosis.
MX9201058A (es) Derivados ciclicos de cetal, procedimiento para supreparacion y composicion farmaceutica que los contiene.
ES2147427T3 (es) Aminas ciclicas n-sustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.